The economic burden of head and neck cancer: a systematic literature review

Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Talia Foster, Chris L Pashos, Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Talia Foster, Chris L Pashos

Abstract

Background: This systematic literature review aimed to evaluate and summarize the existing evidence on resource use and costs associated with the diagnosis and treatment of head and neck cancer (HNC) in adult patients, to better understand the currently available data. The costs associated with HNC are complex, as the disease involves multiple sites, and treatment may require a multidisciplinary medical team and different treatment modalities.

Methods: Databases (MEDLINE and Embase) were searched to identify studies published in English between October 2003 and October 2013 analyzing the economics of HNC in adult patients. Additional relevant publications were identified through manual searches of abstracts from recent conference proceedings.

Results: Of 606 studies initially identified, 77 met the inclusion criteria and were evaluated in the assessment. Most included studies were conducted in the USA. The vast majority of studies assessed direct costs of HNC, such as those associated with diagnosis and screening, radiotherapy, chemotherapy, surgery, side effects of treatment, and follow-up care. The costs of treatment far exceeded those for other aspects of care. There was considerable heterogeneity in the reporting of economic outcomes in the included studies; truly comparable cost data were sparse in the literature. Based on these limited data, in the US costs associated with systemic therapy were greater than costs for surgery or radiotherapy. However, this trend was not seen in Europe, where surgery incurred a higher cost than radiotherapy with or without chemotherapy.

Conclusions: Most studies investigating the direct healthcare costs of HNC have utilized US databases of claims to public and private payers. Data from these studies suggested that costs generally are higher for HNC patients with recurrent and/or metastatic disease, for patients undergoing surgery, and for those patients insured by private payers. Further work is needed, particularly in Europe and other regions outside the USA; prospective studies assessing the cost associated with HNC would allow for more systematic comparison of costs, and would provide valuable economic information to payers, providers, and patients.

Figures

Fig. 1
Fig. 1
Systematic search and screening flow chart. AHNS American Head and Neck Society, ASCO American Society for Clinical Oncology, EHNS European Head and Neck Society, ESMO European Society for Medical Oncology, ISPOR International Society for Pharmacoeconomics and Outcomes Research

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166.
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013.
    1. Howard JD, Chung CH. Biology of human papillomavirus-related oropharyngeal cancer. Semin Radiat Oncol. 2012;22(3):187–193. doi: 10.1016/j.semradonc.2012.03.002.
    1. Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63(1):57–81. doi: 10.3322/caac.21167.
    1. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009;115(5):922–935. doi: 10.1002/cncr.24123.
    1. Chan AT, Gregoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii83–5.
    1. Crombie AK, Farah CS, Batstone MD. Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery. Br J Oral Maxillofac Surg. 2013.
    1. Amonkar MM, Chastek B, Samant N, Teitelbaum A. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ. 2011;14(4):421–432.
    1. Anuradha V, Anand BB, Suresh AVS, Sinha S, Chinna Babu S, Suresh K. Palliative chemotherapy in head and neck squamous cell cancer—what is best in Indian population? A time without symptoms, treatment toxicity score based study. Indian J Med Paediatr Oncol. 2013;34(1):11–15. doi: 10.4103/0971-5851.113404.
    1. Arshad H, Ozer HG, Thatcher A, Old M, Ozer E, Agarwal A, et al. Intensive care unit versus non-intensive care unit postoperative management of head and neck free flaps: comparative effectiveness and cost comparisons. Head Neck. 2013.
    1. Bodard AG, Paris M, Salino S, Fortin T. Evaluation of two noninvasive repositioning systems for computer-assisted oral implant surgery in oral cancer patients. Int J Prosthodont. 2010;23(5):463–468.
    1. Braaksma M, van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer. 2005;41(14):2102–2111. doi: 10.1016/j.ejca.2005.05.012.
    1. Brookes JT, Seikaly H, Diamond C, Mechor B, Harris JR. Prospective randomized trial comparing the effect of early suturing of tracheostomy sites on postoperative patient swallowing and rehabilitation. J Otolaryngol. 2006;35(2):77–82. doi: 10.2310/7070.2005.4035.
    1. Chan JY, Semenov YR, Gourin CG. Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery. Otolaryngol Head Neck Surg. 2013;148(4):602–610. doi: 10.1177/0194599812474595.
    1. Chu CN, Muo CH, Chen SW, Lyu SY, Morisky DE. Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy. BMC Cancer. 2013;13:370. doi: 10.1186/1471-2407-13-370.
    1. Cohen SM, Kim J, Roy N, Asche C, Courey M. The impact of laryngeal disorders on work-related dysfunction. Laryngoscope. 2012;122(7):1589–1594. doi: 10.1002/lary.23197.
    1. Corry J, Poon W, McPhee N, Milner AD, Cruickshank D, Porceddu SV, et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol. 2008;52(5):503–510. doi: 10.1111/j.1440-1673.2008.02003.x.
    1. Corry J, Poon W, McPhee N, Milner AD, Cruickshank D, Porceddu SV, et al. Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. Head Neck. 2009;31(7):867–876. doi: 10.1002/hed.21044.
    1. Coughlan D, Frick KD. Direct medical costs of head and neck cancer in the United States: an analysis using pooled medical expenditure panel survey (MEPS) data. Value Health. 2012;15(4):A235. doi: 10.1016/j.jval.2012.03.1267.
    1. Crandley EF, Wilson DD, Sim A, Blackburn N, Wang L, Rahimi AS, et al. Analysis of treatment costs and outcomes with the addition of induction chemotherapy (IC) to concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC) Int J Radiat Oncol Biol Phys. 2013;87(2):S434–S435. doi: 10.1016/j.ijrobp.2013.06.1146.
    1. Diaz-de-Cerio P, Preciado J, Santaolalla F, Sanchez-Del-Rey A. Cost-minimisation and cost-effectiveness analysis comparing transoral CO(2) laser cordectomy, laryngofissure cordectomy and radiotherapy for the treatment of T1-2, N0, M0 glottic carcinoma. Eur Arch Otorhinolaryngol. 2013;270(4):1181–1188. doi: 10.1007/s00405-012-2139-8.
    1. Donato K, Leszczynski K, Fleming K. A comparative evaluation of two head and neck immobilization devices using electronic portal imaging. Br J Radiol. 2006;79(938):158–161. doi: 10.1259/bjr/32191494.
    1. Dorrian C, Ferguson J, Ah-See K, Barr C, Lalla K, van der Pol M, et al. Head and neck cancer assessment by flexible endoscopy and telemedicine. J Telemed Telecare. 2009;15(3):118–121. doi: 10.1258/jtt.2009.003004.
    1. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–1120. doi: 10.1016/j.ijrobp.2007.01.053.
    1. Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, et al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2006;17(10):1560–1567. doi: 10.1093/annonc/mdl151.
    1. Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. Laryngoscope. 2011;121(1):85–90. doi: 10.1002/lary.21348.
    1. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care. Laryngoscope. 2011;121(4):746–752. doi: 10.1002/lary.21456.
    1. Gourin CG, Frick KD. National trends in oropharyngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care. Laryngoscope. 2012;122(3):543–551. doi: 10.1002/lary.22447.
    1. Gourin CG, Frick KD. National trends in laryngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care. Laryngoscope. 2012;122(1):88–94. doi: 10.1002/lary.22409.
    1. Greskovich JF, Gordian M, Koyfman SA, Lorenz R, Scharpf J, Khan M, et al. Improving healthcare value in patients with stage III–IV squamous cell carcinoma of head and neck (HNSCC): cost and outcome comparison of 2 arms of a randomized, phase 3 trial of definitive chemoradiation (chemoRT) Int J Radiat Oncol Biol Phys. 2013;87(2):S501. doi: 10.1016/j.ijrobp.2013.06.1323.
    1. Hennessey P, Semenov YR, Gourin CG. The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122(10):2199–2204. doi: 10.1002/lary.23459.
    1. Hennessey PT, Francis HW, Gourin CG. Is there a “July effect” for head and neck cancer surgery? Laryngoscope. 2013;123(8):1889–1895. doi: 10.1002/lary.23884.
    1. Jacobson JJ, Epstein JB, Eichmiller FC, Gibson TB, Carls GS, Vogtmann E, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012;4(1):15. doi: 10.1186/1758-3284-4-15.
    1. Jaspers GW, Witjes MJ, Groen HJ, Groen H, Rodiger LA, Roodenburg JL. Strategies for patients with newly diagnosed oral squamous cell carcinoma and a positive chest CT. A cohort study on the effects on treatment planning and incidence. Eur J Surg Oncol. 2011;37(3):272–277. doi: 10.1016/j.ejso.2010.12.012.
    1. Jones NF, Jarrahy R, Song JI, Kaufman MR, Markowitz B. Postoperative medical complications—not microsurgical complications—negatively influence the morbidity, mortality, and true costs after microsurgical reconstruction for head and neck cancer. Plast Reconstr Surg. 2007;119(7):2053–2060. doi: 10.1097/01.prs.0000260591.82762.b5.
    1. Kim K, Amonkar MM, Hogberg D, Kasteng F. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol. 2011;3:47. doi: 10.1186/1758-3284-3-47.
    1. Le Kim T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, et al. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012;15(4):786–795. doi: 10.3111/13696998.2012.682632.
    1. Kochhar A, Pronovost PJ, Gourin CG. Hospital-acquired conditions in head and neck cancer surgery. Laryngoscope. 2013;123(7):1660–1669. doi: 10.1002/lary.23975.
    1. Kurien G, Hu J, Harris J, Seikaly H. Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer. J Otolaryngol Head Neck Surg. 2011;40(6):468–472.
    1. Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130(11):1269–1275. doi: 10.1001/archotol.130.11.1269.
    1. Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009;135(6):582–588. doi: 10.1001/archoto.2009.46.
    1. Li R, Fakhry C, Koch WM, Gourin CG. The effect of tumor subsite on short-term outcomes and costs of care after oral cancer surgery. Laryngoscope. 2013;123(7):1652–1659. doi: 10.1002/lary.23952.
    1. Maddox PT, Davies L. Trends in total laryngectomy in the era of organ preservation: a population-based study. Otolaryngol Head Neck Surg. 2012;147(1):85–90. doi: 10.1177/0194599812438170.
    1. Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health. 2005;8(2):140–148. doi: 10.1111/j.1524-4733.2005.04004.x.
    1. Nijdam W, Levendag P, Noever I, Groot CU, Agthoven M. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol. 2005;77(1):65–72. doi: 10.1016/j.radonc.2005.09.007.
    1. Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008;113(6):1446–1452. doi: 10.1002/cncr.23714.
    1. Patil S, Kumar TN, Mohiyuddin A. Comparison of the use of single and combined antibiotics for head and neck onco-surgeries: a cost effective analysis. J Clin Diagn Res. 2011;5(4):769–771.
    1. Penel N, Lefebvre JL, Cazin JL, Clisant S, Neu JC, Dervaux B, et al. Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. Int J Oral Maxillofac Surg. 2008;37(2):135–139. doi: 10.1016/j.ijom.2007.08.002.
    1. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012.
    1. Pinto M, Uga MA. Cost of treating patients with smoking history in a specialized cancer hospital. Rev Saude Publica. 2011;45(3):575–582. doi: 10.1590/S0034-89102011000300016.
    1. Preuss SF, Quante G, Semrau R, Mueller RP, Klussmann JP, Guntinas-Lichius O. An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma. Laryngoscope. 2007;117(1):101–105. doi: 10.1097/01.mlg.0000246191.90021.5e.
    1. Pryor DI, Porceddu SV, Scuffham PA, Whitty JA, Thomas PA, Burmeister BH. Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. Head Neck. 2013;35(9):1287–1294. doi: 10.1002/hed.23108.
    1. Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, et al. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. J Med Econ. 2013;16(2):221–230. doi: 10.3111/13696998.2012.749789.
    1. Reveles IA, Kreys ED, Corral M, Zhang Y, Koeller JM. Segmented medical costs of squamous cell head and neck cancer: a pharmacoeconomic analysis using a private insurance database. Value Health. 2012;15(4):A216. doi: 10.1016/j.jval.2012.03.1166.
    1. Richmon JD, Quon H, Gourin CG. The effect of transoral robotic surgery on short-term outcomes and cost of care after oropharyngeal cancer surgery. Laryngoscope. 2013.
    1. Ryu J, Nam BH, Jung YS. Clinical outcomes comparing parenteral and nasogastric tube nutrition after laryngeal and pharyngeal cancer surgery. Dysphagia. 2009;24(4):378–386. doi: 10.1007/s00455-009-9213-4.
    1. Santamarta TR, de Villalain L, Peña I, Fernández-del Valle A, Megıas J, de Vicente JC. Abstract PP059. Comparative study of locoregional flaps and free flaps in reconstruction after resection of oral cavity cancer: a cost analysis. Oral Oncol. 2013;49:S114. doi: 10.1016/j.oraloncology.2013.03.302.
    1. Semenov YR, Starmer HM, Gourin CG. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122(9):1994–2004. doi: 10.1002/lary.23446.
    1. Setala L, Koskenvuori H, Gudaviciene D, Berg L, Mustonen P. Cost analysis of 109 microsurgical reconstructions and flap monitoring with microdialysis. J Reconstr Microsurg. 2009;25(9):521–526. doi: 10.1055/s-0029-1238218.
    1. Sheets NC, Wheeler SB, Kohler RE, Fried DV, Brown PM, Chera BS. Costs of care in a matched pair comparison of intensity-modulated radiation therapy (IMRT) versus conventional radiation therapy (CRT) for the treatment of head and neck cancer. Am J Clin Oncol. 2013.
    1. Smeele LE, Goldstein D, Tsai V, Gullane PJ, Neligan P, Brown DH, et al. Morbidity and cost differences between free flap reconstruction and pedicled flap reconstruction in oral and oropharyngeal cancer: matched control study. J Otolaryngol. 2006;35(2):102–107. doi: 10.2310/7070.2005.5001.
    1. St Guily JL, Borget I, Vainchtock A, Remy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol. 2010;2:22. doi: 10.1186/1758-3284-2-22.
    1. Stalfors J, Bjorholt I, Westin T. A cost analysis of participation via personal attendance versus telemedicine at a head and neck oncology multidisciplinary team meeting. J Telemed Telecare. 2005;11(4):205–210. doi: 10.1258/1357633054068892.
    1. Syse A, Tretli S, Kravdal O. Cancer’s impact on employment and earnings—a population-based study from Norway. J Cancer Surviv. 2008;2(3):149–158. doi: 10.1007/s11764-008-0053-2.
    1. Tempest MJ, Thurston S, Carroll SM, Keeping ST. Preliminary results from a study of hospital costs due to treatment of head and neck cancers in England. Value Health. 2012;15(7):A418–A419.
    1. Trivedi NP, Trivedi PH, Trivedi HH, et al. Abstract No. P559. Optimizing multimodality treatment for head and neck cancer in resource constrained rural India. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
    1. Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med. 2010;51(2):176–182. doi: 10.2967/jnumed.109.067371.
    1. van Agthoven M, Heule-Dieleman HA, Knegt PP, Kaanders JH, Baatenburg de Jong RJ, Kremer B, et al. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol. 2006;263(8):729–737. doi: 10.1007/s00405-006-0062-6.
    1. van Hooren AC, Brouwer J, de Bree R, Hoekstra OS, Leemans CR, Uyl-de Groot CA. The cost-effectiveness of 18FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol. 2009;266(9):1441–1448. doi: 10.1007/s00405-008-0878-3.
    1. Vatanasapt P, Thanaviratananich S, Ratanaanekchai T, Thepsuthammarat K. The burden of head and neck cancers in Thailand. J Med Assoc Thai. 2012;95(Suppl 7):S182–S189.
    1. Waters TM, Logemann JA, Pauloski BR, Rademaker AW, Lazarus CL, Newman LA, et al. Beyond efficacy and effectiveness: conducting economic analyses during clinical trials. Dysphagia. 2004;19(2):109–119. doi: 10.1007/s00455-003-0507-7.
    1. Watters K, O’Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol. 2004;118(9):694–699. doi: 10.1258/0022215042244732.
    1. Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99(1):14–23. doi: 10.1093/jnci/djk001.
    1. Arshad H, Old M, Ozer E, et al. Abstract No. S348. ICU vs non ICU postoperative management of head and neck free flaps: comparative effectiveness and cost comparisons. 8th international conference on head and neck cancer, Toronto; 2012.
    1. Grewal AS, Rich JT, Gullane PJ, et al. Abstract No. P558. Cost analysis for surgical treatment of mandibular osteoradionecrosis. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
    1. Hammoudi K, Pinlong E, Kim S. Abstract No. P074. Comparative study between transoral robotic surgery and conventional surgery for treatment of squamous cell carcinoma of the upper aerodigestive tract. American Head & Neck Society Annual Meeting, Orlando; 2013.
    1. Hollenbeak CS, Mackley H, Koch W, et al. Abstract No. S170. Costs associated with head and neck cancer in the elderly. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
    1. O’Connor R, Pezier TF, McGurk M. Abstract No. P106. Cost comparison of elective neck dissection vs sentinel lymph node biopsy in early oral squamous cell carcinoma. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
    1. Pearce AM, Timmons A, Hanly P, et al. Abstract No. PCN146. Workforce participation and productivity losses after head and neck cancer. International Society for Pharmacoeconomics and Outcomes Research 16th annual European Congress, Dublin; 2013.
    1. Razfar A, Grogan T, Lee S, et al. Abstract No. P068. Medicare cost implications in treatment of T1-T3 laryngeal carcinoma. American Head and Neck Society Annual Meeting, Orlando; 2013.
    1. Razfar A, Mundi J, Grogan T, et al. Abstract No. S003. IMRT increases Medicare cost in head and neck cancer patients: A SEER-based study. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
    1. OCEBM. Oxford Centre for Evidence-based Medicine—Levels of Evidence 1; 2009. . Cited 2 Dec 2013.
    1. OCEBM Levels of Evidence Working Group, Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, et al. The Oxford Levels of Evidence 2; 2013. . Cited 2 Dec 2013.
    1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128. doi: 10.1093/jnci/djq495.
    1. Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100(24):1763–1770. doi: 10.1093/jnci/djn384.
    1. Serrier H, Sultan-Taieb H, Luce D, Bejean S. Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France. Eur J Health Econ. 2013.
    1. American Cancer Society. Cancer treatment & survivorship facts & figures 2012–2013; 2013. . Cited 2 Dec 2013.
    1. SEER. SEER Stat Fact Sheets: oral cavity and pharynx cancer; 2013. . Cited 2 Dec 2013.
    1. ERBITUX® (cetuximab) website; 2013. . Cited 28 Nov 2013.
    1. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Technol. 2010;38(1):6–17. doi: 10.2967/jnmt.108.059584.
    1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238(2):405–422. doi: 10.1148/radiol.2382041977.
    1. Trivedi NP, Trivedi P, Trivedi H, Trivedi S, Trivedi N. Optimizing multimodality treatment for head and neck cancer in rural India. Indian J Cancer. 2012;49(2):225–229. doi: 10.4103/0019-509X.102917.
    1. Blackwell KE, Azizzadeh B, Ayala C, Rawnsley JD. Octogenarian free flap reconstruction: complications and cost of therapy. Otolaryngology Head Neck Surg. 2002;126(3):301–306. doi: 10.1067/mhn.2002.122704.
    1. Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL. Economic burden of head and neck cancer. A literature review. Eur J Health Econ. 2004;5(1):70–80. doi: 10.1007/s10198-003-0204-3.
    1. Himmel M, Hartmann M, Guntinas-Lichius O. Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. Oncology. 2013;84(6):336–341. doi: 10.1159/000350006.
    1. Cuckler GA, Sisko AM, Keehan SP, Smith SD, Madison AJ, Poisal JA, et al. National health expenditure projections, 2012–2022: slow growth until coverage expands and economy improves. Health Aff (Millwood) 2013;32(10):1820–1831. doi: 10.1377/hlthaff.2013.0721.
    1. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012;17(4):469–492. doi: 10.1517/14728214.2012.744393.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다